Thus, it may be worth considering that, in addition to MYCN amplification status, levels of EIF4EBP1 expression could help identifying patients carrying clinically more aggressive tumors within the stage 4 NB patients group. The gene discussed is EIF4EBP1; the disease is neuroblastoma.